Products for Research Use Only
RegisterLogin

Levofloxacin

CAT: 0804-HY-B0330-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0330-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Levofloxacin ((-) -Ofloxacin) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin inhibits the DNA gyrase and topoisomerase IV. Levofloxacin can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin shows anti-orthopoxvirus activity[1][2][3][4][5].
CAS Number
100986-85-4
Product Name Alternative
(-) -Ofloxacin
UNSPSC
12352005
Hazard Statement
H302, H317, H334, H361, H362
Target
Antibiotic; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage
Applications
COVID-19-anti-virus
Field of Research
Infection; Cancer
Assay Protocol
https://www.medchemexpress.com/Levofloxacin.html
Purity
99.96
Solubility
DMSO : 10 mg/mL (ultrasonic) |H2O : ≥ 5 mg/mL
Smiles
O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O
Molecular Formula
C18H20FN3O4
Molecular Weight
361.37
Precautions
H302, H317, H334, H361, H362
References & Citations
[1]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61 (3) :377-92. |[2]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57 (1-2) :41-52.|[3]Rand A, et al. Effect of levofloxacin on some body tissues in mice. Effect of levofloxacin on some body tissues in mice. Iraqi Journal of Veterinary Sciences, 2021.|[4]JI B, et al. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39 (6) :1341-4.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
Quinolone; Topoisomerase
Citation 01
ACS Infect Dis. 2024 Apr 12;10 (4) :1327-1338.|Acta Pharm Sin B. 2025 Sep 19.|AMB Express. 2024 Dec 24;14 (1) :141.|Antibiotics (Basel) . 2022 Feb 1;11 (2) :192.|Antimicrob Agents Chemother. 2021 Feb 17;65 (3) :e01921-20.|bioRxiv. 2024 May 10.|bioRxiv. 2025 January 19.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Chin J Traumatol. 2024 Jul 3:S1008-1275 (24) 00075-0.|Clin Chem. 2019 Dec;65 (12) :1522-1531. |Commun Biol. 2025 Oct 6;8 (1) :1425.|Diagn Microbiol Infect Dis. 2025 Nov 4;114 (2) :117181.|EBioMedicine. 2025 May 30:117:105776.|Eur J Clin Microbiol Infect Dis. 2025 Sep 29.|Future Microbiol. 2025 Oct 13:1-10.|Infect Genet Evol. 2025 Sep:133:105780.|Int J Antimicrob Agents. 2025 Jun 9:107551.|Microbiol Spectr. 2025 May 19:e0307424.|Microbiol Spectr. 2025 Oct 15:e0122125.|Nat Commun. 2025 May 10;16 (1) :4366.|PLoS One. 2024 Apr 18;19 (4) :e0298577.|Res Sq. 2025 Aug 05.|Results Chem. 2024 Oct.|SSRN. 2025 Oct 14.|Toxics. 2025 Feb 5;13 (2) :122.|Water. 2025 Jun 6.|Emerg Microbes Infect. 2024 Dec;13 (1) :2321981.|J Med Virol. 2025 Oct;97 (10) :e70655.|Nat Commun. 2022 Mar 2;13 (1) :1116.

Alternative Products

CatalogName
B1959-5.1Levofloxacin

Popular Products